PROCEPT BioRobotics (PRCT) Equity Average (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Equity Average data on file, last reported at $356.8 million in Q1 2026.

• Quarterly Equity Average fell 9.84% year-over-year to $356.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356.8 million (down 9.84% YoY) and the FY2025 annual result came in at $384.0 million, up 12.46% from the prior year.
• Equity Average retreated to $356.8 million in Q1 2026 per PRCT's latest filing, from $373.1 million in the prior quarter.
• Across five years, Equity Average topped out at $395.7 million in Q1 2025 and bottomed at $164.5 million in Q2 2023.
• The 5-year median for Equity Average is $259.9 million (2022), against an average of $282.7 million.
• The widest annual swing landed in 2022, when Equity Average jumped 497.29%; it then tumbled 33.12% in 2023.
• Tracing PRCT's Equity Average over 5 years: stood at $208.9 million in 2022, then soared by 38.84% to $290.1 million in 2023, then grew by 10.92% to $321.7 million in 2024, then advanced by 15.96% to $373.1 million in 2025, then slipped by 4.37% to $356.8 million in 2026.
• Per Business Quant, the three latest PRCT Equity Average figures stand at $356.8 million (Q1 2026), $373.1 million (Q4 2025), and $383.0 million (Q3 2025).

Peer Comparison